Contineum Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
CTNM$10.30+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $21,943 | $15,526 |
| Marketable securities | 182,817 | 109,664 |
| Prepaid expenses and other current assets | 1,628 | 2,516 |
| Total current assets | 206,388 | 127,706 |
| Property and equipment, net | 989 | 678 |
| Other long-term assets | 3 | 1,283 |
| Operating lease right-of-use assets | 5,467 | 719 |
| Total assets | $212,847 | $130,386 |
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,811 | $635 |
| Accrued expenses | 6,711 | 4,385 |
| Current portion of operating lease liabilities | 1,452 | 464 |
| Total current liabilities | 9,974 | 5,484 |
| Other long-term liabilities | — | 110 |
| Operating lease liabilities, net of current portion | 4,807 | 108 |
| Total liabilities | 14,781 | 5,702 |
| Commitments and contingencies (Note 11) | ||
| Convertible preferred stock, $0.001 par value; no shares authorized, issued, or outstanding at December 31, 2024; authorized shares—16,940,594 at December 31, 2023; issued and outstanding shares—15,906,236 shares at December 31, 2023. | — | 192,620 |
| Stockholders’ equity (deficit): | ||
| Class A common stock, $0.001 par value; authorized shares—200,000,000 and 39,630,511 at December 31, 2024 and December 31, 2023, respectively; issued and outstanding shares—19,125,377 and 2,349,554 at December 31, 2024 and December 31, 2023, respectively. | 19 | 2 |
| Class B common stock, $0.001 par value; authorized shares—20,000,000 at December 31, 2024; issued and outstanding shares—6,729,172 at December 31, 2024; no shares authorized, issued, or outstanding at December 31, 2023. | 7 | — |
| Preferred stock, $0.001 par value; authorized shares—10,000,000 at December 31, 2024; no shares issued or outstanding at December 31, 2024; no shares authorized, issued, or outstanding at December 31, 2023 | — | — |
| Additional paid-in-capital | 315,371 | 7,098 |
| Accumulated deficit | (117,402) | (75,144) |
| Accumulated other comprehensive income | 71 | 108 |
| Total stockholders’ equity (deficit) | 198,066 | (67,936) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $212,847 | $130,386 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.